Moneycontrol PRO
aurobindo pharma
Jump to
888 Results Found
  • Buy Aurobindo Pharma; target of Rs 880: Motilal Oswal Jun 07, 2020 08:36 PM IST

    Buy Aurobindo Pharma; target of Rs 880: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 880 in its research report dated June 04, 2020.

  • Hold Aurobindo Pharma target of Rs 840: Sharekhan Jun 07, 2020 08:35 PM IST

    Hold Aurobindo Pharma target of Rs 840: Sharekhan

    Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 840 in its research report dated June 04, 2020.

  • Accumulate Aurobindo Pharma; target of Rs 838: Prabhudas Lilladher Jun 07, 2020 08:26 PM IST

    Accumulate Aurobindo Pharma; target of Rs 838: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 838 in its research report dated June 05, 2020.

  • Buy Aurobindo Pharma; target of Rs 835: HDFC Securities Jun 07, 2020 08:18 PM IST

    Buy Aurobindo Pharma; target of Rs 835: HDFC Securities

    HDFC Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 835 in its research report dated June 05, 2020.

  • Buy Aurobindo Pharma; target of Rs 920: ICICI Direct Jun 07, 2020 08:04 PM IST

    Buy Aurobindo Pharma; target of Rs 920: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 920 in its research report dated May 05, 2020.

  • Aurobindo Pharma likely to become debt-free by FY22: Key highlights of concall Jun 06, 2020 04:26 PM IST

    Aurobindo Pharma likely to become debt-free by FY22: Key highlights of concall

    Aurobindo Pharma's R&D expense for FY21 is expected to be at 5.5% of sales as the clinical trials for Biosimilars & differentiated products starts.

  • Buy Aurobindo Pharma; target of Rs 870: ICICI Securities Jun 05, 2020 11:56 AM IST

    Buy Aurobindo Pharma; target of Rs 870: ICICI Securities

    ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 870 in its research report dated June 04, 2020.

  • Aurobindo: Traction in complex generics is vital to its health Jun 05, 2020 10:03 AM IST

    Aurobindo: Traction in complex generics is vital to its health

  • Buy Aurobindo Pharma; target of Rs 786: Emkay Global Financial Jun 05, 2020 09:37 AM IST

    Buy Aurobindo Pharma; target of Rs 786: Emkay Global Financial

    Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 786 in its research report dated June 03, 2020.

  • Aurobindo Pharma share price gains 2% after CLSA raises target price Jun 05, 2020 09:35 AM IST

    Aurobindo Pharma share price gains 2% after CLSA raises target price

    CLSA increased FY21-22 EPS estimates by 8-10%.

  • FDA issues Form 483 with 9 observations to Aurobindo Pharma's USA facility Jun 04, 2020 04:47 PM IST

    FDA issues Form 483 with 9 observations to Aurobindo Pharma's USA facility

    The plant which makes oral solid manufacturing is situated at Dayton, New Jersey and was inspected by the FDA authorities from January 13, 2020 to February 12, 2020.

  • Aurobindo Pharm Standalone March 2020 Net Sales at Rs 3,620.32 crore, up 10.36% Y-o-Y Jun 04, 2020 01:13 PM IST

    Aurobindo Pharm Standalone March 2020 Net Sales at Rs 3,620.32 crore, up 10.36% Y-o-Y

  • Aurobindo Pharm Consolidated March 2020 Net Sales at Rs 6,158.43 crore, up 16.37% Y-o-Y Jun 04, 2020 01:13 PM IST

    Aurobindo Pharm Consolidated March 2020 Net Sales at Rs 6,158.43 crore, up 16.37% Y-o-Y

  • Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies Jun 03, 2020 07:46 AM IST

    Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies

    The stock shot up 149 percent from its March lows especially after increased focus on healthcare worldwide due to COVID-19 crisis.

  • Buy Aurobindo Pharma; target of Rs 790: HDFC Securities May 15, 2020 11:24 AM IST

    Buy Aurobindo Pharma; target of Rs 790: HDFC Securities

    HDFC Securities bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 790 in its research report dated May 13, 2020.

  • Aurobindo Pharma, promoters settle insider trading case with SEBI May 14, 2020 05:55 PM IST

    Aurobindo Pharma, promoters settle insider trading case with SEBI

    The three other entities that have settled the matter with the regulator are Kambam P Reddy, Trident Chemphar Ltd and Veritaz Health Care Ltd.

  • Aurobindo Pharma shares jump 3% after Credit Suisse upgrade, raises target to Rs 665/sh Apr 22, 2020 10:46 AM IST

    Aurobindo Pharma shares jump 3% after Credit Suisse upgrade, raises target to Rs 665/sh

    Credit Suisse is of the view that progress on net debt reduction has been good so far but is concerned on low growth outlook with earnings growth seen in single digits.

  • Aurobindo Pharma gets VAI classification from USFDA for Hyderabad unit Apr 21, 2020 02:16 PM IST

    Aurobindo Pharma gets VAI classification from USFDA for Hyderabad unit

    Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI).

  • Aurobindo Pharma share price surges 17% after FDA's VAI status for Hyderabad unit Apr 21, 2020 10:14 AM IST

    Aurobindo Pharma share price surges 17% after FDA's VAI status for Hyderabad unit

    The US regulator determined the inspection classification of the company's Hyderabad unit as Voluntary Action Indicated (VAI), the company said in a filing to the exchanges.

  • Aurobindo Pharma share price jumps 6% on USFDA nod for antidepressant Apr 09, 2020 12:52 PM IST

    Aurobindo Pharma share price jumps 6% on USFDA nod for antidepressant

    Aurobindo said this was the first ANDA to be approved out of APL Healthcare formulation facility in Hyderabad.

  • Aurobindo Pharma share price gains 4% despite calling off deal with Sandoz Apr 03, 2020 12:39 PM IST

    Aurobindo Pharma share price gains 4% despite calling off deal with Sandoz

    Credit Suisse has downgraded the stock to underperform from neutral and has slashed target from Rs 450 to Rs 345 per share as USFDA approvals may remain weak.

  • Aurobindo Pharma, Sandoz Inc call off $900 million deal Apr 02, 2020 07:35 PM IST

    Aurobindo Pharma, Sandoz Inc call off $900 million deal

    Aurobindo Pharma on Thursday said the USD 900 million deal to acquire Sandoz Inc's US-based generic oral solids and dermatology businesses has been mutually called off.

  • Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod Apr 02, 2020 08:45 AM IST

    Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

    Novartis said the decision to terminate the sale of Sandoz US's generic oral solids and dermatology businesses was taken after the companies did not get approval from the U.S. Federal Trade Commission within anticipated timelines.

  • Aurobindo Pharma share price jumps 11% after US FDA nod for muscle relaxant Mar 27, 2020 10:17 AM IST

    Aurobindo Pharma share price jumps 11% after US FDA nod for muscle relaxant

    The stock hit upper circuit of Rs 397.50 per share. It was quoting at Rs 399.00, up Rs 37.60, or 10.40 percent.

  • Hot Stocks: Here's why you should sell Aurobindo Pharma, HUL in the short term Mar 11, 2020 08:52 AM IST

    Hot Stocks: Here's why you should sell Aurobindo Pharma, HUL in the short term

    A level below 10150 could drag the Nifty towards 9,800 support, derived from 61.8% Fibonacci Fan of the swing seen from 6825 (Feb 2016 Bottom) to 12430 (Jan 2020 Top).

Sections
ISO 27001 - BSI Assurance Mark